Clinical Trials Directory

Trials / No Longer Available

No Longer AvailableNCT03723057

Expanded Access for AG-221

Status
No Longer Available
Phase
Study type
Expanded Access
Enrollment
Sponsor
Celgene · Industry
Sex
All
Age
18 Years
Healthy volunteers

Summary

This is an expanded access program (EAP) for eligible participants designed to provide access to AG-221.

Conditions

Interventions

TypeNameDescription
DRUGAG-221Oral AG-221 administered as directed by treating physician.

Timeline

First posted
2018-10-29
Last updated
2019-10-24

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT03723057. Inclusion in this directory is not an endorsement.

Expanded Access for AG-221 (NCT03723057) · Clinical Trials Directory